• About Us
    • Contact Us
    • Login
    • ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
About Us Contact Us Login ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
COVID-19 Clinical Outcomes

Coronavirus and COVID-19: Clinical Characteristics from 138 Patients in Wuhan, China

image_pdfFavoriteLoadingFavorite

BACKGROUND AND PURPOSE:

  • Wang et al. (JAMA, 2020) described clinical and epidemiological characteristics of patients with COVID-19 in Wuhan, China

METHODS:

  • Retrospective, single-center case series
  • Participants
    • All 138 consecutive hospitalized patients with confirmed COVID-19 at Zhongnan Hospital of Wuhan University in Wuhan, China from January 1 to January 28, 2020
  • Exposures
    • Documented cases
  • Study design
    • The following data were collected: epidemiological, demographic, clinical, laboratory, radiological, and treatment data
    • The authors compared outcomes of critically ill patients and noncritically ill patients

RESULTS:

  • 138 patients | Median age was 56 (Range, 22-92 years) | 54.3% were men
  • Hospital-associated transmission was suspected as the presumed mechanism of infection for
    • Affected health professionals: 29%
    • Hospitalized patients: 12.3%

Symptoms

  • Common symptoms
    • Fever: 98.6%
    • Fatigue: 69.6%
    • Dry cough: 59.4%
  • Lymphopenia: 70.3%
    • Lymphocyte count, 0.8 × 109/L (interquartile range [IQR], 0.6 to 1.1)
  • Prolonged prothrombin time: 58%
    • 13.0 seconds (IQR, 12.3 to 13.7)
  • Elevated lactate dehydrogenase: 39.9%
    • 261 U/L (IQR, 182 to 403)
  • CT findings: Bilateral patchy shadows or ground glass opacity in the lungs of all patients

Therapies and Treatment

  • Antiviral therapy
    • Oseltamivir: 89.9%
  • Antibacterial therapy
    • Moxifloxacin: 64.4%
    • Ceftriaxone: 24.6%
    • Azithromycin: 18.1%
  • Glucocorticoid therapy: 44.9%

ICU Admission

  • ICU transfer rate: 26.1%
  • Indications for transfer
    • ARDS: 61.1%
    • Arrhythmia: 44.4%
    • Shock: 30.6%
  • Median time from first symptom to
    • Dyspnea: 5.0 days
    • Hospital admission: 7.0 days
    • ARDS: 8.0 days
  • Compared to patients not treated in the ICU (n = 102), patients treated in the ICU (n = 36) were
    • Older: Median age: 66 years vs 51 years
    • More likely to have underlying comorbidities: 72.2% vs 37.3%
    • More likely to have dyspnea: 63.9% vs 19.6%
    • More likely to have anorexia: 66.7% vs 30.4%
  • Of the 36 cases in the ICU
    • 11.1% received high-flow oxygen therapy
    • 41.7% received noninvasive ventilation
    • 47.2% received invasive ventilation (4 were switched to ECMO)

Outlook

  • Discharged: 34.1%
  • Mortality: 4.3%
  • Among those discharged alive Median hospital stay was 10 days (IQR, 7.0 to 14.0)
  • Many of the patients were still hospitalized at the time of publication

CONCLUSION:

  • The authors did not find use of antibacterial agents, oseltamivir or methylprednisolone to be effective
  • The authors further state that

…abnormalities suggest that 2019-nCoV infection may be associated with cellular immune deficiency, coagulation activation, myocardia injury, hepatic injury, and kidney injury

These laboratory abnormalities are similar to those previously observed in patients with MERS-CoV and SARS-CoV infection

Learn More – Primary Sources:

Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus–Infected Pneumonia in Wuhan, China

Get COVID-19 Research Summaries Direct to Your Phone, with ObGFirst

Try it Free »

image_pdfFavoriteLoadingFavorite
< Previous
All COVID-19 Clinical Outcomes Posts
Next >

Related ObG Topics:

Coronavirus and Pregnancy: CDC Guidance and Professional Recommendations
COVID-19 Guidance: Key Highlights for Healthcare Professionals

Sections

  • COVID-19
  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • Grand Rounds
  • My Bookshelf
  • Now@ObG
  • Media

Are you an
ObG Insider?

Get specially curated clinical summaries delivered to your inbox every week for free

  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Download Your ObG App
HERE!

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Already a Member of ObGFirst®?

Please log in to ObGFirst to access the 2T US Atlas

Password Trouble?

Not an ObGFirst® Member Yet?

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!
ObGFirst Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site